These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24737137)

  • 21. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
    Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
    PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
    Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
    J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.
    Namkung W; Park J; Seo Y; Verkman AS
    Mol Pharmacol; 2013 Sep; 84(3):384-92. PubMed ID: 23788656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.
    Stanton BA; Coutermarsh B; Barnaby R; Hogan D
    PLoS One; 2015; 10(5):e0127742. PubMed ID: 26018799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
    Bacalhau M; Ferreira FC; Kmit A; Souza FR; da Silva VD; Pimentel AS; Amaral MD; Buarque CD; Lopes-Pacheco M
    Eur J Pharmacol; 2023 Jan; 938():175396. PubMed ID: 36410419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-guided combination therapy to potently improve the function of mutant CFTRs.
    Veit G; Xu H; Dreano E; Avramescu RG; Bagdany M; Beitel LK; Roldan A; Hancock MA; Lay C; Li W; Morin K; Gao S; Mak PA; Ainscow E; Orth AP; McNamara P; Edelman A; Frenkiel S; Matouk E; Sermet-Gaudelus I; Barnes WG; Lukacs GL
    Nat Med; 2018 Nov; 24(11):1732-1742. PubMed ID: 30297908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation.
    Rapino D; Sabirzhanova I; Lopes-Pacheco M; Grover R; Guggino WB; Cebotaru L
    PLoS One; 2015; 10(3):e0119796. PubMed ID: 25799511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
    Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS
    J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein.
    He L; Kota P; Aleksandrov AA; Cui L; Jensen T; Dokholyan NV; Riordan JR
    FASEB J; 2013 Feb; 27(2):536-45. PubMed ID: 23104983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
    Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
    J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.
    Fiorotto R; Amenduni M; Mariotti V; Fabris L; Spirli C; Strazzabosco M
    Hepatology; 2018 Mar; 67(3):972-988. PubMed ID: 28836688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
    Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
    Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.